If the business you invest in fails, you are likely to lose 100% of the money you invested. Most start-up businesses fail. Even if the business you invest in is successful, it may take several years ...

This memo is original content created by Howard Marks, Co-Chairman of Oaktree Capital Management (“Oaktree”), and published on 6 November. It is reproduced here with Oaktree’s permission. The views ...

In today’s Budget, the Chancellor announced a package of tax changes to support scaling companies to attract investment and talent. The government is increasing the amount of capital VCT and EIS ...

Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early. The most likely way to get your money ...

In the early 1990s, Northern Irish former schoolteacher Kevin McNeany had a vision – to transform the language and training business he established in 1972, by opening British-style private schools ...

On 24 October, YFM Equity Partners, manager of the British Smaller Companies VCTs, announced the profitable sale of its stake in Elucidat. The Brighton-based learning technology company has been ...

In her pre-Budget speech on 4 November, Chancellor Rachel Reeves prepared the ground for new “necessary” tax hikes, with a call for “all” to contribute. It's the clearest sign yet that the tax ...

On Wednesday 15 October, Chancellor Rachel Reeves confirmed she is looking at “further measures on tax” ahead of next month's Budget, as she tries to plug a fiscal hole of anything between £20bn and ...

Compelling investments for experienced investors: Wealth Club is the UK’s largest non-advisory investment service for high net worth and experienced investors, with over 00,000 members. Below is a ...

On 3 October 2025, home-use beauty technology business The Beauty Tech Group (“TBTG”) – the largest holding in the Northern VCTs – made its debut on the London Stock Exchange, one of the few new IPOs ...

Gresham House – the manager of the Baronsmead VCTs – recently announced its successful exit from clinical trial specialists Panthera Biopartners, following a significant investment from private equity ...